Filing Analysis
Theriva Biologics announced the results of a Type D meeting with the FDA regarding its lead clinical candidate, VCN-01, for the treatment of pancreatic adenocarcinoma (PDAC). The FDA advised against expanding the current Phase 2b study into a Phase 3 trial, recommending instead a stand-alone Phase 3 study.
🚩 Red Flags
- Clinical pathway change: The FDA's recommendation to pivot from expanding the current trial to a new stand-alone Phase 3 study may imply increased capital requirements and longer timelines for drug approval.
📋 Key Facts
- FDA Type D meeting held to discuss Phase 3 design for VCN-01 in combination with standard-of-care chemotherapy.
- FDA advised against expanding the ongoing VIRAGE Phase 2b study into a Phase 3 study.
- Optimal path identified by FDA: conduct a stand-alone Phase 3 study of VCN-01 with gemcitabine/nab-paclitaxel.
- FDA agreed with proposed design and noted that adding additional chemotherapy would complicate analysis.
- The VIRAGE Phase 2b study has completed target enrollment.
Theriva Biologics, Inc. filed an 8-K to announce the release of its financial results for the quarter ended September 30, 2024.
📋 Key Facts
- The filing is a standard disclosure of quarterly results under Item 2.02.
- Reporting period: Quarter ended September 30, 2024.
- Filing date: November 12, 2024.
- The company issued a press release (Exhibit 99.1) containing the financial information.
Theriva Biologics, Inc. reported the results of its 2024 Annual Meeting of Stockholders, which included significant shareholder approvals for increasing authorized share counts and amending the company's stock incentive plan.
🚩 Red Flags
- Massive increase in authorized share count (from 14M to 350M) suggests significant potential for future dilution through equity offerings.
- Significant expansion of the Stock Incentive Plan (nearly 9x increase) indicates substantial upcoming dilution via employee/director compensation.
📋 Key Facts
- Stockholders approved Amendment No. 2 to the 2020 Stock Incentive Plan, increasing the share limit from 280,000 to 2,500,000 shares.
- Stockholders approved an amendment to the Articles of Incorporation to increase authorized common stock from 14,000,000 to 350,000,000 shares.
- Four directors (Jeffrey J. Kraws, Steven A. Shallcross, John Monahan, and Jeffrey Wolf) were elected to the Board.
- BDO USA, P.C. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- The company filed a Certificate of Change in Nevada effective November 1, 2024, to reflect the increase in authorized shares.
Theriva Biologics announced that the European Medicines Agency (EMA) has recommended granting orphan medicinal product designation to its lead clinical candidate, VCN-01, for the treatment of retinoblastoma.
📋 Key Facts
- Date of announcement: October 16, 2024
- Regulatory body: European Commission/European Medicines Agency (EMA)
- Candidate name: VCN-01 (oncolytic adenovirus)
- Indication: Retinoblastoma
- Designation type: Orphan medicinal product designation
Theriva Biologics announced positive DSMC results for its Phase 1b/2a trial of SYN-004, recommending the study proceed to Cohort 3. However, the company explicitly noted it is currently pursuing additional funding to finance this next phase.
🚩 Red Flags
- Company explicitly stated it is 'pursuing additional funding' to enable the conduct of Cohort 3, indicating potential liquidity constraints or upcoming dilution.
📋 Key Facts
- DSMC recommended proceeding to Cohort 3 for SYN-004 (ribaxamase) in HCT recipients.
- Cohort 3 will involve administration of study drug or placebo in combination with cefepime.
- No Adverse Events (AEs) or Serious Adverse Events (SAEs) were determined by investigators to be related to the study drug.
- 15 SAEs reported among 10 patients, primarily infections/sepsis, but deemed typical for allo-HCT patients and unrelated to the drug.
- Pharmacokinetics of piperacillin were as expected in this patient population.
Theriva Biologics, Inc. completed a public offering of common stock and warrants on September 27, 2024, raising approximately $2.5 million in gross proceeds. The offering includes pre-funded warrants and common warrants that will lead to significant future dilution.
🚩 Red Flags
- Significant potential dilution from the issuance of over 1.9 million warrants/pre-funded warrants relative to current outstanding shares.
- The offering price ($1.75) is relatively low, suggesting a need for immediate liquidity.
- Restrictive covenants in the Purchase Agreement prevent certain equity offerings for up to 6 months.
📋 Key Facts
- Offering closed on September 27, 2024.
- Gross proceeds of approximately $2.5 million before fees.
- Offered 918,600 shares of common stock at $1.75 per share (combined with warrants).
- Issued 510,000 Pre-Funded Warrants exercisable at $0.0001 per share.
- Issued Common Warrants for up to 1,428,600 shares with an exercise price of $2.00 per share.
- Placement Agent (A.G.P./Alliance Global Partners) charged a 7.0% fee plus up to $100,000 in expenses.
- Post-offering common stock outstanding: 2,272,462 shares (assuming no warrant exercise).
Theriva Biologics announced the completion of patient enrollment for its VIRAGE Phase 2b clinical trial evaluating VCN-01 in combination with chemotherapy for metastatic pancreatic cancer. The company also intends to conduct several investor presentations in the coming weeks.
📋 Key Facts
- Achieved target enrollment of 92 evaluable patients in the VIRAGE Phase 2b clinical trial.
- The trial evaluates VCN-01 plus standard-of-care (SoC) chemotherapy for metastatic pancreatic ductal adenocarcinoma (PDAC).
- VCN-01 has received FDA Orphan Drug Designation and Fast Track Designation for PDAC.
- Phase 1 data previously showed an overall response rate of 83% in a small cohort (n=6) with median progression-free survival of 6.3 months.
- Total of 142 patients have been administered VCN-01 across all indications to date.
Theriva Biologics announced a €2.28 million funding award from the Spanish government's National Knowledge Transfer Program for its THERICEL project. The funding includes a €1.33 million unsecured loan to the company and a €0.95 million grant to Universitat Autònoma de Barcelona (UAB) to advance viral therapy manufacturing platforms.
🚩 Red Flags
- The funding is structured as an unsecured loan rather than a pure grant, creating a future repayment obligation.
📋 Key Facts
- Total award amount: €2.28 million from Spain's Ministry of Science, Innovation & Universities.
- Company component: Receives an unsecured loan of €1.33 million as a lump sum in Q4 2024.
- Loan terms: 4.015% interest rate; repayment over 7 years starting three years from the award date.
- Partner component: UAB receives a €0.95 million grant paid in annual installments over 3 years.
- Purpose: To advance the THERICEL suspension cell platform for clinical manufacture of adenovirus and AAV therapies.
Theriva Biologics, Inc. announced the conversion of all remaining Series C and Series D Convertible Preferred Stock into common stock as of September 6, 2024.
🚩 Red Flags
- Conversion price of $30.50 is significantly higher than typical micro-cap trading prices (suggests potential dilution if market price is lower, though total share count increase here is minimal).
📋 Key Facts
- Conversion date: September 6, 2024
- Series C Conversion: 4,138 shares converted to 1,086 common shares at $30.50 per share.
- Series D Conversion: 100,000 shares converted to 26,230 common shares at $30.50 per share.
- Total new common shares issued: 27,316 shares.
- Resulting status: No Series C or Series D Convertible Preferred Stock remains outstanding.
Theriva Biologics, Inc. has implemented a 1-for-25 reverse stock split effective August 26, 2024. The action was taken specifically to maintain compliance with the NYSE American per share price requirements.
🚩 Red Flags
- Reverse stock split (typically indicates significant downward pressure on share price or delisting risk).
- Explicitly stated purpose is to meet NYSE American per share price requirements, indicating a struggle to maintain minimum listing standards.
📋 Key Facts
- Reverse stock split ratio is 1:25 (one new share for every 25 old shares).
- Effective date of the split: August 26, 2024, at 12:01 a.m. ET.
- Outstanding shares reduced from 25,131,230 to approximately 1,005,249 shares.
- The split was executed via a Certificate of Change filed in Nevada.
- No fractional shares will be issued; stockholders with fractions will be rounded up to the nearest whole share.
Theriva Biologics, Inc. has approved a 1-for-25 reverse stock split to maintain compliance with NYSE American listing requirements regarding minimum share price.
🚩 Red Flags
- Reverse stock split is being executed specifically to avoid delisting from the NYSE American due to per share price requirements.
- Significant reduction in total outstanding shares (approx. 96% reduction).
📋 Key Facts
- Reverse stock split ratio: 1-for-25.
- Effective date: Expected at 12:01 a.m. ET on August 26, 2024.
- Share count reduction: Outstanding shares expected to decrease from 25,131,230 to approximately 1,005,249.
- Fractional shares will be rounded up to the nearest whole share; no cash in lieu of fractional shares will be paid.
- The trading symbol remains 'TOVX' and a new CUSIP (87164U 508) has been assigned.
Theriva Biologics, Inc. filed an 8-K to announce the release of its financial results for the quarter ended June 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Financial information pertains to the quarter ended June 30, 2024.
- The report was filed on August 13, 2024.
Theriva Biologics announced that the FDA granted Rare Pediatric Drug Designation (RPDD) for its lead candidate, VCN-01, for treating retinoblastoma. Additionally, a holder of Series C Convertible Preferred Stock converted 135,431 shares into 888,072 shares of common stock.
🚩 Red Flags
- Significant dilution potential due to the conversion of Series C Preferred Stock into a large block of common stock (888,072 shares).
📋 Key Facts
- FDA granted Rare Pediatric Drug Designation (RPDD) for VCN-01 for the treatment of retinoblastoma on July 30, 2024.
- VCN-01 is a systemic, selective, stroma-degrading oncolytic adenovirus.
- The company previously received orphan drug designation for VCN-01 for the same indication.
- Series C Convertible Preferred Stock conversion: 135,431 preferred shares converted into 888,072 common shares.
- Conversion price was set at $1.22 per share.
Theriva Biologics announced that the FDA has granted Fast Track Designation (FTD) to its lead clinical candidate, VCN-01, for use in combination with chemotherapy to treat metastatic pancreatic adenocarcinoma. This follows a previous Orphan Drug Designation for the same candidate.
📋 Key Facts
- FDA granted Fast Track Designation (FTD) to VCN-01 in combination with gemcitabine and nab-paclitaxel.
- Target indication: metastatic pancreatic adenocarcinoma (PDAC).
- The drug is currently being evaluated in the VIRAGE Phase 2b multinational clinical study.
- VCN-01 previously received Orphan Drug Designation for PDAC treatment.
Theriva Biologics, Inc. announced the conversion of 135,431 shares of Series C Convertible Preferred Stock into 888,072 shares of common stock.
🚩 Red Flags
- Potential dilution for existing common shareholders due to the issuance of 888,072 new shares.
📋 Key Facts
- Conversion date: May 13, 2024
- Shares converted: 135,431 shares of Series C Convertible Preferred Stock
- Common stock issued: 888,072 shares
- Conversion price: $1.22 per share
Theriva Biologics, Inc. filed an 8-K to announce the release of its financial results for the quarter ended March 31, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly financial results (Item 2.02).
- Financial information pertains to the fiscal quarter ending March 31, 2024.
- The company issued a press release on May 7, 2024, which is incorporated by reference as Exhibit 99.1.
Theriva Biologics entered into Amendment No. 2 to its At-The-Market (ATM) sales agreement with A.G.P./Alliance Global Partners and simultaneously terminated B. Riley Securities, Inc. as a party to the same agreement.
🚩 Red Flags
- Continued use of ATM offerings suggests ongoing need for liquidity/capital raising.
📋 Key Facts
- Entered into Amendment No. 2 to the Amended and Restated Sales Agreement on May 2, 2024.
- The agreement allows the Company to sell common stock through A.G.P./Alliance Global Partners via an 'at the market' offering.
- B. Riley Securities, Inc. was removed from the Sales Agreement effective May 1, 2024, by mutual agreement.
- Sales will be conducted under a current or newly filed Form S-3 registration statement.
Theriva Biologics announced positive topline Phase 1 trial data for VCN-01 in pediatric patients with refractory retinoblastoma. As a result of these clinical outcomes, the company will receive an exclusive worldwide license and related patents from Sant Joan de Déu-Barcelona Children’s Hospital.
🚩 Red Flags
- Observed ocular inflammation and turbidity post-injection (managed with anti-inflammatories).
📋 Key Facts
- Phase 1 Trial results for intravitreal VCN-01 in pediatric patients with refractory retinoblastoma were positive.
- 9 evaluable patients were included in the study (n=1 at 2x10^9 vp/eye; n=8 at 2x10^10 vp/eye).
- Safety profile: No dose-limiting toxicities or Grade 3+ ocular/systemic toxicities reported.
- Clinical outcome: 4 patients showed unequivocal improvement in vitreous seed density; enucleation avoided in 3 patients to date.
- The company will receive an exclusive, worldwide license and related patents from Sant Joan de Déu-Barcelona Children’s Hospital.
Theriva Biologics announced preclinical data demonstrating synergistic anti-tumor effects when combining its lead product candidate, VCN-01, with liposomal irinotecan in pancreatic cancer mouse models. The company plans to present these findings at the ASGCT 27th Annual Meeting on May 10, 2024.
📋 Key Facts
- Preclinical data shows enhanced viral protein expression in human pancreatic cancer cell lines when exposed to topo1 inhibitors like irinotecan.
- In vivo mouse xenograft models showed significant tumor growth inhibition for VCN-01 alone and liposomal irinotecan alone.
- Combination therapy (VCN-01 + liposomal irinotecan) demonstrated significantly reduced tumor growth compared to monotherapies.
- qPCR analysis confirmed ongoing transcriptional activity of VCN-01 in tumors, suggesting viral replication for several days post-administration.
Theriva Biologics, Inc. announced its intention to conduct several investor presentations over the coming weeks. The company provided a corporate presentation as an exhibit under Regulation FD disclosure.
📋 Key Facts
- The Company will be making multiple investor presentations in the weeks following April 16, 2024.
- A corporate presentation dated April 2024 was furnished as Exhibit 99.1.
- Information provided under Item 7.01 is not considered 'filed' for purposes of Section 18 or liability under Sections 11 and 12(a)(2).
- The filing includes safe harbor language regarding forward-looking statements.
Theriva Biologics, Inc. issued an 8-K to announce the release of its financial results for the fiscal year ended December 31, 2023.
📋 Key Facts
- The filing is a standard announcement of year-end financial results (Item 2.02).
- Financial information pertains to the fiscal year ending December 31, 2023.
- The report was filed on March 25, 2024.
Theriva Biologics announced that an Independent Data Monitoring Committee (IDMC) recommended continuing enrollment for its Phase 2b VIRAGE clinical trial. The committee found no safety concerns and confirmed the feasibility of repeated systemic dosing of VCN-01.
📋 Key Facts
- The IDMC recommended continuation of enrollment in the VIRAGE Phase 2b trial without protocol changes.
- The trial evaluates VCN-01 combined with gemcitabine/nab-paclitaxel for metastatic pancreatic ductal adenocarcinoma (PDAC).
- Clinical data showed no new safety concerns or additional toxicities from second doses of VCN-01.
- Enrollment is on track to complete in the first half of 2024.
- Trial sites are active across 6 locations in the U.S. and 9 locations in Spain.
Theriva Biologics, Inc. announced its intention to conduct several investor presentations over the coming weeks. The company provided a corporate presentation as an exhibit to facilitate these communications.
📋 Key Facts
- The company will be making multiple presentations to investors starting in January 2024.
- A corporate presentation dated January 2024 was furnished as Exhibit 99.1.
- Information provided under Item 7.01 is not considered 'filed' for purposes of Section 18 or liability under Sections 11 and 12(a)(2) of the Securities Act.